Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.…
Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration
Arcturus Therapeutics Holdings (NASDAQ: ARCT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 106 employees.
The shares were at 7.450 USD on 20 November 2026, down 14.6% over 52 weeks. Its 52-week range is 5.500 USD to 17.75 USD: the price is 58.0% below the high and 35.5% above the low.
Its market capitalisation is 214.73M USD.
Arcturus Therapeutics Holdings reports return on equity of -30.7%, an operating margin of -311.2% and revenue up 6.7% year over year.
It holds more cash than debt, a net cash position of 162.95M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 10 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 23.70 USD is 218.1% above the current price. The next earnings report is expected on 2 March 2027.